What is the recommended diagnostic work‑up and treatment for bronchiolitis obliterans in a child?

Bronchiolitis Obliterans in Children: Diagnostic Work-up and Treatment

Immediate Diagnostic Approach

For postinfectious bronchiolitis obliterans (the most common form in children), diagnosis relies on the combination of clinical history (particularly prior severe respiratory infection, especially adenovirus), persistent obstructive lung disease on spirometry, and characteristic high-resolution CT findings—lung biopsy is rarely necessary. 1

Essential Diagnostic Components

Clinical History:

• Document prior severe lower respiratory tract infection, with adenovirus being the most common trigger (25% of postinfectious cases), followed by measles pneumonia (21.9%) and RSV 2
• Look for persistent cough, wheezing, and crackles on examination that do not resolve after the acute infection 2
• Consider alternative etiologies: Stevens-Johnson syndrome (9.5% of cases) or post-transplant settings 2

Pulmonary Function Testing:

• Perform spirometry showing fixed obstructive pattern (FEV1 decline with reduced FEV1/FVC ratio) 1
• Constrictive obstruction occurs in 89.7% of cases, with mixed pattern in 10.3% 2
• Static lung volumes and DLCO should be obtained where feasible 3

High-Resolution CT Imaging:

• Obtain inspiratory and expiratory views to demonstrate air trapping 3
• Look for mosaic perfusion (present in 81% of cases), bronchiectasis (33.3%), bronchial wall thickening (33.3%), and vascular attenuation 1, 2
• These findings combined with clinical history are sufficiently diagnostic in most cases, avoiding the need for lung biopsy 1

Bronchoscopy with BAL:

• Perform to rule out bacterial suppurative airway disease and ongoing infection 3
• This is particularly important before initiating immunosuppressive therapy 4

Treatment Algorithm

Post-Transplant Bronchiolitis Obliterans Syndrome (BOS)

First-Line Therapy:

• Initiate azithromycin 250 mg daily for 5 days, then 250 mg three times weekly for minimum 3 months 4
• Switch from cyclosporine to tacrolimus (target trough 5-15 ng/mL) if currently on cyclosporine-based immunosuppression 4
• Avoid long-term high-dose corticosteroids (>30 mg/day prednisone) as they provide minimal benefit with increased adverse effects 4

Address Underlying Factors:

• Aggressively treat any coexisting infections 4
• Consider surgical fundoplication for confirmed gastroesophageal reflux disease 4

Progressive Disease:

• Consider extracorporeal photopheresis (ECPP) or total lymphoid irradiation (TLI) for refractory cases 4
• Evaluate for lung re-transplantation in end-stage disease 4

Postinfectious Bronchiolitis Obliterans (PIBO)

Important distinction: Macrolide therapy (azithromycin) used for post-transplant BOS has no documented role in toxic/antigenic exposure-related or postinfectious bronchiolitis obliterans. 5

Emerging Evidence for PIBO Treatment:

• For severe PIBO with physiological deterioration, consider combination therapy with intravenous pulse methylprednisolone (IVPM) 10 mg/kg/day for 3 days plus intravenous immunoglobulin (IVIG) 1 g/kg for 2 days, administered monthly for 6 months 6
• This regimen showed 83.3% clinical improvement, with significant reduction in annual wheezing episodes (from 3.12 to 1.25, p=0.014) and hospitalization rates (from 2.12 to 0.50, p<0.001) 6
• Early initiation at younger age and earlier disease stages appears more effective 6
• Only transient hyperglycemia and mild rash were observed as side effects 6

Alternative IVIG Monotherapy:

• For patients with subtle immunological abnormalities or severe disease despite standard therapy, regular IVIG treatment showed favorable clinical and radiological responses 7
• This approach led to decreased hospital visits, discontinued oxygen therapy, and improved radiological severity scores 7

Supportive Care:

• Bronchodilator inhalation therapy 2
• Oral montelukast 2
• Low-dose macrolides (erythromycin or azithromycin) may be used as part of supportive care in PIBO, though evidence is limited 2

Post-HSCT BOS Surveillance Protocol

For children post-hematopoietic stem cell transplant, implement active surveillance rather than waiting for symptoms:

• Begin spirometry, static lung volumes, and DLCO at 3 months post-HSCT 3
• Perform testing every 3 months during first year post-HSCT 3
• Continue every 3-6 months during second year 3
• Transition to every 6 months between years 2-3, then annually until 10 years post-HSCT 3
• Obtain chest CT with inspiratory/expiratory views pre-HSCT and when obstructive lung function develops 3

Critical Pitfalls to Avoid

• Do not rely on chest radiographs—they are neither sensitive nor specific for BOS diagnosis 3
• Do not assume all pediatric BO is progressive—postinfectious BO is generally chronic but nonprogressive, unlike Stevens-Johnson syndrome-related BO which often progresses 1
• Do not delay treatment initiation in severe PIBO cases—early intervention with IVPM/IVIG appears more effective 6
• Do not use azithromycin for postinfectious BO expecting the same benefits seen in post-transplant BOS—the mechanisms differ 5

Prognosis

• Most postinfectious BO cases have poor long-term outcomes with current standard therapy, with only rare cases showing amelioration 2
• Prognosis relates to underlying cause and severity of initial insult 1
• Post-transplant BOS affects >50% of recipients surviving beyond 5 years and is the leading cause of death after 1 year post-transplant 3